October 27, 2017 / 8:53 PM / 3 months ago

Merck withdraws marketing application for Keytruda in Europe

(Reuters) - Merck & Co Inc (MRK.N) said on Friday it had withdrawn its European application for Keytruda as a combination treatment for patients with an advanced stage of non-small cell lung cancer.

    The company’s shares tumbled 8.9 percent to $56.50 (43.05 pounds)in after-hours trading.

    Earlier in the day, the U.S. drugmaker said quarterly sales of Keytruda exceeded $1 billion for the first time in the third quarter.

    Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below